Clinical Trial Update: Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients [Phase 2]

View source ↗

Summary

Phase 2 placebo-controlled trial evaluating safety, tolerability, PK, and PD of SAP-001 in gout patients with hyperuricemia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• SAP-001

Snippet

Sponsor: Shanton Pharma Co., Ltd. | Conditions: Gout, Hyperuricemia | Phase 2 | Status: COMPLETED